Biomedical Science Letters (대한의생명과학회지)

The Korean Society for Biomedical Laboratory Sciences (대한의생명과학회)
권호 표지
DOI QR코드

DOI QR Code

Anticancer Drugs at Low Concentrations Upregulate the Activity of Natural Killer Cell

  • Hyeokjin Kwon (Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan) ;
  • Myeongguk Jeong (Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan) ;
  • Yeeun Kim (Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan) ;
  • Go-Eun Choi (Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan)
  • Received : 2023.08.22
  • Accepted : 2023.09.13
  • Published : 2023.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Natural killer (NK) cells are innate cytotoxic lymphoid cells that actively prevent neoplastic development, growth, and metastatic dissemination in a process called cancer immunosurveillance. Regulation of the cytotoxic activity of NK cells relies on integrated interactions between inhibitory receptors and numerous activating receptors that act in tandem to eliminate tumor cells efficiently. Conventional chemotherapy is designed to produce an anti-proliferative or cytotoxic effect on early tumor cell division. Therapies designed to kill cancer cells and simultaneously maintain host anti-tumor immunity are attractive strategies for controlling tumor growth. Depending on the drug and dose used, several chemotherapeutic agents cause DNA damage and cancer cell death through apoptosis, immunogenic cell death, or other forms of non-killing (i.e., mitotic catastrophe, senescence, autophagy). Among stress-induced immunostimulatory proteins, changes in the expression levels of NK cell activating and inhibitory ligands and tumor cell death receptors play an important role in the detection and elimination by innate immune effectors including NK cells. Therefore, we will address how these cytotoxic lymphocytes sense and respond to high and low concentrations of drug-induced stress to the drug cisplatin, among the various types of drugs that contribute to their anticancer activity.

Keywords

Acknowledgement

This study was supported by academic research funds from the Catholic University of Pusan in 2021.

References

  1. Abel AM, Yang C, Thakar MS, Malarkannan S. Natural killer cells: Development, maturation, and clinical utilization. Frontiers in Immunology. 2018. 9: 1869.
  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians. 2018. 68: 394-424. https://doi.org/10.3322/caac.21492
  3. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox R, Tattersall M. On the receiving end-patient perception of the side-effects of cancer chemotherapy. European Journal of Cancer and Clinical Oncology. 1983. 19: 203-208. https://doi.org/10.1016/0277-5379(83)90418-2
  4. Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Kroemer G. Prognostic and predictive impact of intra-and peritumoral immune infiltrates. Cancer Research. 2011. 71: 5601-5605. https://doi.org/10.1158/0008-5472.CAN-11-1316
  5. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012. 31: 1869-1883. https://doi.org/10.1038/onc.2011.384
  6. Gawel S, Wardas M, Niedworok E, Wardas P. Malondialdehyde (mda) as a lipid peroxidation marker. Wiadomosci lekarskie (Warsaw, Poland: 1960). 2004. 57: 453-455.
  7. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 2001. 478: 23-43. https://doi.org/10.1016/S0027-5107(01)00141-5
  8. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, Cheng J, Goedert JJ, Vlahov D, Hilgartner M. Hla and nk cell inhibitory receptor genes in resolving hepatitis c virus infection. Science. 2004. 305: 872-874. https://doi.org/10.1126/science.1097670
  9. Kumar S. Natural killer cell cytotoxicity and its regulation by inhibitory receptors. Immunology. 2018. 154: 383-393. https://doi.org/10.1111/imm.12921
  10. Kwon H-J, Choi G-E, Ryu S, Kwon SJ, Kim SC, Booth C, Nichols KE, Kim HS. Stepwise phosphorylation of p65 promotes nf-κb activation and nk cell responses during target cell recognition. Nature Communications. 2016. 7: 11686.
  11. Lake RA, Robinson BW. Immunotherapy and chemotherapy-a practical partnership. Nature Reviews Cancer. 2005. 5: 397-405. https://doi.org/10.1038/nrc1613
  12. Lanier LL. Up on the tightrope: Natural killer cell activation and inhibition. Nature Immunology. 2008. 9: 495-502. https://doi.org/10.1038/ni1581
  13. Lee W-C, Wong H-Y, Chai Y-Y, Shi C-W, Amino N, Kikuchi S, Huang S-H. Lipid peroxidation dysregulation in ischemic stroke: Plasma 4-hne as a potential biomarker? Biochemical and Biophysical Research Communications. 2012. 425: 842-847. https://doi.org/10.1016/j.bbrc.2012.08.002
  14. Lorenzo-Herrero S, Lopez-Soto A, Sordo-Bahamonde C, Gonzalez-Rodriguez AP, Vitale M, Gonzalez S. Nk cell-based immunotherapy in cancer metastasis. Cancers. 2018. 11: 29.
  15. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F. Induced recruitment of nk cells to lymph nodes provides ifn-γ for th1 priming. Nature Immunology. 2004. 5: 1260-1265. https://doi.org/10.1038/ni1138
  16. Morvan MG, Lanier LL. Nk cells and cancer: You can teach innate cells new tricks. Nature Reviews Cancer. 2016. 16: 7-19. https://doi.org/10.1038/nrc.2015.5
  17. Nam T-G. Lipid peroxidation and its toxicological implications. Toxicological Research. 2011. 27: 1-6. https://doi.org/10.5487/TR.2011.27.1.001
  18. R Shurin M, Naiditch H, W Gutkin D, Umansky V, V Shurin G. Chemoimmunomodulation: Immune regulation by the antineoplastic chemotherapeutic agents. Current Medicinal Chemistry. 2012. 19: 1792-1803. https://doi.org/10.2174/092986712800099785
  19. ROBINSON S. The family with cancer. European Journal of Cancer Care. 1992. 1: 29-33. https://doi.org/10.1111/j.1365-2354.1992.tb00108.x
  20. Schirrmacher V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment. International Journal of Oncology. 2019. 54: 407-419. https://doi.org/10.3892/ijo.2018.4661
  21. Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SE, Yagita H, Takeda K, Van Dommelen SL, Degli-Esposti MA, Hayakawa Y. Activation of nk cell cytotoxicity. Molecular Immunology. 2005. 42: 501-510. https://doi.org/10.1016/j.molimm.2004.07.034
  22. Srivastava S, Lundqvist A, Childs R. Natural killer cell immunotherapy for cancer: A new hope. Cytotherapy. 2008. 10: 775-783. https://doi.org/10.1080/14653240802648181
  23. Tan S, Turner J, Kerin-Ayres K, Butler S, Deguchi C, Khatri S, Mo C, Warby A, Cunningham I, Malalasekera A. Health concerns of cancer survivors after primary anti-cancer treatment. Supportive Care in Cancer. 2019. 27: 3739-3747. https://doi.org/10.1007/s00520-019-04664-w
  24. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science. 2011. 331: 44-49. https://doi.org/10.1126/science.1198687
  25. Wallin RP, Screpanti V, Michaelsson J, Grandien A, Ljunggren HG. Regulation of perforin-independent nk cell-mediated cytotoxicity. European Journal of Immunology. 2003. 33: 2727-2735. https://doi.org/10.1002/eji.200324070
  26. Wu S-Y, Fu T, Jiang Y-Z, Shao Z-M. Natural killer cells in cancer biology and therapy. Molecular Cancer. 2020. 19: 1-26. https://doi.org/10.1186/s12943-020-01238-x
  27. Zingoni A, Fionda C, Borrelli C, Cippitelli M, Santoni A, Soriani A. Natural killer cell response to chemotherapy-stressed cancer cells: Role in tumor immunosurveillance. Frontiers in Immunology. 2017. 8: 1194.
  28. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nature Reviews Immunology.2008. 8: 59-73. https://doi.org/10.1038/nri2216
  29. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nature Reviews Clinical Oncology. 2011. 8: 151-160. https://doi.org/10.1038/nrclinonc.2010.223